Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm3)

[1]  E. Oermann,et al.  Clinical Characteristics and Management of Late Urinary Symptom Flare Following Stereotactic Body Radiation Therapy for Prostate Cancer , 2014, Front. Oncol..

[2]  M. Steinberg,et al.  Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. , 2013, International journal of radiation oncology, biology, physics.

[3]  J. Galvin,et al.  Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. , 2013, International journal of radiation oncology, biology, physics.

[4]  Jason Wang,et al.  Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  P. Hoskin,et al.  The influence of prostate volume on outcome after high-dose-rate brachytherapy alone for localized prostate cancer. , 2013, International journal of radiation oncology, biology, physics.

[6]  John T. Wei,et al.  Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. , 2013, International journal of radiation oncology, biology, physics.

[7]  M. Santoro,et al.  Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years , 2013, Radiation oncology.

[8]  A. Zietman,et al.  Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer , 2013, Cancer.

[9]  E. Oermann,et al.  Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience , 2013, Radiation Oncology.

[10]  E. Oermann,et al.  Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer , 2013, Radiation oncology.

[11]  J. Crook,et al.  Androgen deprivation therapy: minimizing exposure and mitigating side effects. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  M. Zelefsky,et al.  Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[13]  R. Persad,et al.  HDR Brachytherapy in the Management of High-Risk Prostate Cancer , 2012, Advances in urology.

[14]  James D Brooks,et al.  Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[15]  E. Oermann,et al.  Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy , 2011, Front. Oncol..

[16]  I. Kaplan,et al.  Hypofractionated Stereotactic Body Radiotherapy in Low Risk Prostate Adenocarcinoma: Preliminary Results of a Multi-Institutional Phase I Feasibility Trial , 2011 .

[17]  R. Peschel,et al.  The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy. , 2011, International journal of radiation oncology, biology, physics.

[18]  C. King,et al.  Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes , 2011, Radiation oncology.

[19]  Kyounghwa Bae,et al.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Santoro,et al.  Stereotactic body radiotherapy for organ-confined prostate cancer , 2010, BMC urology.

[21]  W. J. Morris,et al.  Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. , 2009, International journal of radiation oncology, biology, physics.

[22]  G. Viani,et al.  Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. , 2009, International journal of radiation oncology, biology, physics.

[23]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[24]  Y. Yamada,et al.  Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[25]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[26]  J. Fowler,et al.  Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. , 2007, International journal of radiation oncology, biology, physics.

[27]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[28]  J. Fowler,et al.  The radiobiology of prostate cancer including new aspects of fractionated radiotherapy , 2005, Acta oncologica.

[29]  M. Litwin,et al.  Variation in continence and potency by definition. , 2003, The Journal of urology.

[30]  R. Stock,et al.  Urinary symptom flare following I-125 prostate brachytherapy. , 2003, International journal of radiation oncology, biology, physics.

[31]  D. Theodorescu,et al.  The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapy. , 2003, European urology.

[32]  G. Norman,et al.  Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.

[33]  L. Potters,et al.  Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[34]  J. Blasko,et al.  Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study. , 2002, International journal of radiation oncology, biology, physics.

[35]  K. Wallner,et al.  Long-term urinary function after transperineal brachytherapy for patients with large prostate glands. , 2001, International journal of radiation oncology, biology, physics.

[36]  H M Sandler,et al.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. , 2000, Urology.

[37]  N Lee,et al.  Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.

[38]  C C Ling,et al.  Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[40]  W Cavanagh,et al.  Use of TRUS to predict pubic arch interference of prostate brachytherapy. , 1999, International journal of radiation oncology, biology, physics.

[41]  J. Ware,et al.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. , 1996, Medical care.

[42]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[43]  John T. Wei,et al.  Comparative effectiveness of external-beam radiation approaches for prostate cancer. , 2014, European urology.

[44]  Dong Han Lee,et al.  Image-Guided Stereotactic Body Radiation Therapy for Localized Prostate Cancer , 2011, Tumori.

[45]  C. Lawton,et al.  Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial , 2010 .

[46]  C. Anderson,et al.  Radiation Oncology , 2001, Springer International Publishing.

[47]  Avid,et al.  INTRAFRACTIONAL MOTION OF THE PROSTATE DURING HYPOFRACTIONATED RADIOTHERAPY , 2009 .

[48]  M. Eble,et al.  Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[49]  W. Lee,et al.  Hypofractionation for prostate cancer: a critical review. , 2008, Seminars in radiation oncology.

[50]  G. Pond,et al.  Long-term urinary sequelae following 125iodine prostate brachytherapy. , 2008, The Journal of urology.

[51]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[52]  K. Wallner,et al.  The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. , 2006, International journal of radiation oncology, biology, physics.

[53]  Butler Wm,et al.  Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56:899-905. , 2006 .

[54]  L. Potters,et al.  Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. , 1999, International journal of radiation oncology, biology, physics.